Mostrar el registro sencillo del ítem

Artículo

dc.creatorRíos Martín, Juan Josées
dc.creatorRodríguez Salas, Nuriaes
dc.creatorVázquez Doval, Francisco Javieres
dc.creatorLlombart, Beatrizes
dc.creatorRojas Ferrer, Noheliaes
dc.creatorGonzález Vela, M. Carmenes
dc.creatorIdoate Gastearena, Miguel Ángeles
dc.creatorDe las Peñas, Ramónes
dc.date.accessioned2022-11-29T13:57:44Z
dc.date.available2022-11-29T13:57:44Z
dc.date.issued2022
dc.identifier.citationRíos Martín, J.J., Rodríguez Salas, N., Vázquez Doval, F.J., Llombart, B., Rojas Ferrer, N., González Vela, M.C.,...,De las Peñas, R. (2022). Clinical and pathological features of Merkel cell carcinoma: A 4-year follow-up observational retrospective study in Spain. Cancer Epidemiology, 76, 102081. https://doi.org/10.1016/j.canep.2021.102081.
dc.identifier.issn1877-7821es
dc.identifier.issn1877-783Xes
dc.identifier.urihttps://hdl.handle.net/11441/139893
dc.description.abstractBackground: Merkel cell carcinoma (MCC) is a malignant skin cancer with a 5-year survival rate of approximately 50%. Knowledge of MCC has increased in recent years mostly due to improved diagnosis techniques. In Spain there is lack of information regarding the incidence and tumour characteristics, and the treatment approaches are not standardised. The objective of this study was to provide information of the clinical and epidemiological characteristics of MCC patients in Spain. Methods: Retrospective, observational study involving 192 patients from 25 Spanish hospitals. Evaluated vari ables included overall survival and incidence rate of Merkel cell polyomavirus, in patients diagnosed from 2012 to 2016. Results: The Spanish incidence rate was estimated 0.32/100,000 inhabitants/year, with variations according to geographical regions, being slightly higher in areas with greater sunlight exposure. In total, 61.5% of tumours showed expansive growth (progressive growth of the tumour), 78.6% showed localisation in UV-exposed skin. 97.4% of patients were diagnosed by excisional biopsy. Surgery was the first line treatment in 96.6% of patients, radiotherapy in 24.6%, and chemotherapy in 6.3%. These treatments were not mutually exclusive. Median overall survival was 38.3 months (78.4% at 12 months and 60% at 24 months). MCPyV was present in 33.8% of patients. Conclusion: The incidence of MCC in Spain is one of the highest in Europe, with a slight predominance in men. The sample has shown that a biopsy is available for diagnosis in most cases. Moreover, the treatment is surgical when the tumour is localized and is associated with lymphadenectomy, and/or it is radiotherapy if widespread.es
dc.formatapplication/pdfes
dc.format.extent6 p.es
dc.language.isoenges
dc.publisherElsevier LTD.es
dc.relation.ispartofCancer Epidemiology, 76, 102081.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectMerkel cell carcinomaes
dc.subjectClinicales
dc.subjectPathologicales
dc.subjectFeatures Spaines
dc.titleClinical and pathological features of Merkel cell carcinoma: A 4-year follow-up observational retrospective study in Spaines
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Citología e Histología Normal y Patológicaes
dc.relation.publisherversionhttps://www.sciencedirect.com/science/article/pii/S1877782121001983?via%3Dihubes
dc.identifier.doi10.1016/j.canep.2021.102081es
dc.journaltitleCancer Epidemiologyes
dc.publication.volumen76es
dc.publication.initialPage102081es

FicherosTamañoFormatoVerDescripción
Clinical and pathological.pdf605.9KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional